Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

Executive Summary

AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.

You may also be interested in...



Brilinta Boost For AZ In Stroke Study

"Synergy Search" Lies Behind AZ's Combined CV, Diabetes and Renal Ops

The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.

Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts

Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel